Trial Profile
A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Conatus Pharmaceuticals
- 18 Sep 2014 New trial record